经皮尼古丁治疗肺结节病的随机对照预试验
这项随机双盲对照预试验纳入50例活动性肺结节病患者,每日经皮尼古丁21 mg或安慰剂治疗24周。26周时尼古丁组FVC较基线改善约2.1%(70 mL),安慰剂组下降2.2%,组间净增140 mL(95%CI 10-260)。尼古丁耐受良好,无严重不良事件或成瘾证据。
要点
- 经皮尼古丁21 mg/日治疗24周在活动性肺结节病患者中耐受良好。
- 26周时尼古丁组FVC较安慰剂组净增140 mL(95%CI 10-260)。
- FEV1和疲劳评分仅轻微改善,肺纹理评分等未改善。
核心结论
- 尼古丁治疗在活动性肺结节病患者中耐受良好,基于FVC的初步发现提示可能减缓疾病进展。
研究设计与样本
- 随机、双盲、安慰剂对照预试验,每日经皮尼古丁贴片21 mg或安慰剂治疗24周。
- 共纳入50例年龄≥18岁、有症状且影像学提示非纤维化肺病的活动性肺结节病患者。
主要发现
- 尼古丁组FVC从基线至26周改善约2.1%(70 mL),安慰剂组下降2.2%,组间净增140 mL(95%CI 10-260)。
- 尼古丁组FEV1和疲劳评估评分较安慰剂组仅轻微改善。
- 肺纹理评分、疲劳评估评分、圣乔治呼吸问卷评分和结节病评估工具均未见改善。
- 未报告严重不良事件或尼古丁成瘾证据。
临床怎么用
- 该预试验结果提示经皮尼古丁可能减缓活动性肺结节病患者的FVC下降,但需更大样本验证。
局限性
- 为预试验,样本量50例,结果需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tobacco smoking is associated with a reduced risk of developing sarcoidosis, and we previously reported that nicotine normalizes immune responses to environmental antigens in patients with active pulmonary sarcoidosis. The effects of nicotine on the progression of pulmonary sarcoidosis are unknown. RESEARCH QUESTION: Is nicotine treatment well tolerated, and will it improve lung function in patients with active pulmonary sarcoidosis? STUDY DESIGN AND METHODS: With local institutional review board approval, a randomized, double-blind, controlled pilot trial was conducted of daily nicotine transdermal patch treatment (21 mg daily) or placebo patch use for 24 weeks. The Ohio State University Wexner Medical Center and Cleveland Clinic enrolled 50 consecutive subjects aged ≥ 18 years with active pulmonary sarcoidosis, based on symptoms (ie, dyspnea, cough) and objective radiographic evidence of infiltrates consistent with nonfibrotic lung disease. Each study group was compared at 26 weeks based on repeated measures of FVC, FEV1, quantitative lung texture score based on CT texture analysis, Fatigue Assessment Score (FAS), St. George's Respiratory Questionnaire (SGRQ), and the Sarcoidosis Assessment Tool. RESULTS: Nicotine treatment was associated with a clinically significant, approximately 2.1% (70 mL) improvement in FVC from baseline to 26 weeks. FVC decreased by a similar amount (2.2%) in the placebo group, with a net increase of 140 mL (95% CI, 10-260) when comparing nicotine vs placebo groups at 26 weeks. FEV1 and FAS improved marginally in the nicotine-treated group, compared with those on placebo. No improvement was observed in lung texture score, FAS, St. George's Respiratory Questionnaire score, or the Sarcoidosis Assessment Tool. There were no reported serious adverse events or evidence of nicotine addiction. INTERPRETATION: Nicotine treatment was well tolerated in patients with active pulmonary sarcoidosis, and the preliminary findings of this pilot study suggest that it may reduce disease progression, based on FVC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02265874; URL: www.clinicaltrials.gov.
引用
- Crouser ED, Smith RM, Culver DA, et al. A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis. Chest. 2021. PMID: 34029565. doi:10.1016/j.chest.2021.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。